Abstract
CGE22-098: Correlation Between Trough Level of Abiraterone Acetate and PSA Response in Metastatic Hormone Sensitive Prostate Cancer
Journal of the National Comprehensive Cancer Network, Vol.20(3.5), p.CGE22-098
03/31/2022
DOI: 10.6004/jnccn.2021.7155
Abstract
Background: Studies have demonstrated that in patients with metastatic hormone sensitive prostate cancer (mHSPC), a prostate-specific antigen (PSA) level at 7-months of ≤ 0.2 ng/ml is associated with a longer overall survival than a 7-month PSA ≥ 4 ng/ml. We aimed to explore 1) correlation between abiraterone acetate (ABI) trough plasma concentrations and PSA levels, and 2) association between ABI and 3-month PSA ≤1 ng/ml and 7-month PSA ≤0.2ng/ml in mHSPC. Methods: This is a single center, prospective, observational study in patients with mHSPC treated with ABI 1000mg daily on an empty stomach. ABI trough levels and PSA levels were drawn at 1, 3, and 7-months after starting ABI. Trough plasma concentrations of ABI were correlated with PSA levels by Spearman correlation coefficient. ABI levels were associated with 3-months PSA ≤ 1 ng/ml and 7-months PSA ≤ 0.2 ng/ml by Logistic regression. Results: Thirteen patients were included. The median age was 64 (56-83); 11 were Caucasian and 2 African-American. Ten patients presented with de novo mHSPC while three patients received prior definitive therapy and later developed mHSPC. Ten patients had high volume disease and 3 had low volume disease as defined per CHARRTED. The median PSA at diagnosis was 132 (57-4279). There was high inter-patient variability in ABI trough levels; the mean ABI trough level at 1-month, 3-months, and 7-months was 34.49 ng/ml (3.36-240.46), 13.82 ng/ml (2.91-29.96) and 29.8 ng/ml (3.58-26.86) respectively. The correlation between 1-month ABI trough and 1-month PSA level was 0.18 (p = 0.5), between 3-month ABI trough and 3-month PSA was -0.64 (p = 0.04), and between 7-month ABI trough and 7-month PSA was 0.07 (p = 0.8). There was no significant association between ABI trough and 3-months PSA ≤ 1 ng/ml (p = 0.17) and 7-months PSA ≤ 0.2 ng/ml (p = 0.5). At a median of 11 months (3-14) of follow up, 9 patients were still alive (one patient had a CR, 5 had a PR, and 3 had SD) and 4 patients had disease progression and died from prostate cancer. Conclusions: There was a statistically significant negative correlation between 3-months ABI trough levels and 3-month PSA levels; higher ABI trough levels correlated with a lower 3-month PSA. There was no association between ABI trough and 3-months PSA ≤ 1 and 7-months PSA ≤ 0.2. Our sample size is small, however, this is a preliminary report and enrollment is ongoing.
Details
- Title: Subtitle
- CGE22-098: Correlation Between Trough Level of Abiraterone Acetate and PSA Response in Metastatic Hormone Sensitive Prostate Cancer
- Creators
- Zin Myint - Markey Cancer CenterJill Kolesar - University of KentuckyJoseph R McCorkle - University of KentuckyJianrong Wu - University of KentuckyCarleton S Ellis - Markey Cancer CenterDanielle E Otto - Markey Cancer CenterPeng Wang - University of Kentucky
- Resource Type
- Abstract
- Publication Details
- Journal of the National Comprehensive Cancer Network, Vol.20(3.5), p.CGE22-098
- DOI
- 10.6004/jnccn.2021.7155
- ISSN
- 1540-1405
- eISSN
- 1540-1413
- Language
- English
- Date published
- 03/31/2022
- Academic Unit
- Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics
- Record Identifier
- 9984696552502771
Metrics
1 Record Views